scFv(GPC3)-CD3zeta CAR-T Lentivirus

scFv(GPC3)-CD3zeta CAR-T lentivirus is a highly efficient and stable gene delivery system designed to modify T cells for targeted cancer therapy. As a viral vector, lentiviruses offer numerous significant advantages, making them the gold standard for laboratory research and clinical production. One of the key characteristics of lentiviral vectors is their ability to efficiently transduce dividing and non-dividing cells, crucial for processing primary human T lymphocytes with potentially different metabolic states. Unlike other viral systems, lentiviral particles facilitate the stable integration of chimeric antigen receptor (CAR) transgenes into the host cell genome. This ensures that the anti-GPC3 CAR is inherited by daughter cells during T cell proliferation, resulting in sustained long-term receptor expression. From a safety perspective, these lentiviral particles are typically designed as self-inactivating (SIN) systems. This design renders the virus incapable of replication and minimizes the risk of insertional mutations, thus providing a safety guarantee for the development of therapeutic drugs.

The application of scFv(GPC3)-CD3zeta CAR-T lentiviruses primarily focuses on developing immunotherapies for solid tumors expressing Glypican-3 (GPC3), with hepatocellular carcinoma (HCC) being the primary target. GPC3 is an oncoemulsifiable protein that is significantly upregulated on the surface of HCC cells but is virtually absent in healthy adult tissues, providing an ideal window for therapeutic intervention with minimal off-target toxicity. In preclinical studies, this lentiviral system is used for important in vitro experiments, such as evaluating the antigen-specific cytotoxicity of modified T cells against GPC3-positive cell lines and detecting the secretion of key inflammatory cytokines, such as interferon-γ (IFN-γ). Furthermore, these particles are crucial for in vivo studies using mouse xenograft models, enabling the assessment of CAR-T cell infiltration into solid tumor tissues, overcoming tumor microenvironment inhibition, and inducing tumor regression.